Golimumab Phase 3 Data Show Significant Improvement In Physical Function In Patients With Rheumatoid Arthritis

Results from two Phase 3 studies showed that patients receiving every four week subcutaneous injections of golimumab (CNTO 148) 50 mg or 100 mg, an investigational therapy, experienced significant improvements in physical function, health-related quality of life (HRQOL) and fatigue.